← Back to Search

Behavioral Intervention

Enhanced early detection for Autism

Phase 4

Waitlist Available

Led By Diana Robins, PhD

Research Sponsored by Drexel University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 48 m, 60 m; 60 minutes

Awards & highlights

Study Summary

This trial seeks to improve outcomes for kids with ASD by early detection and intervention.

Eligible Conditions

Autism
Autism Spectrum Disorder

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 48 m, 60 m; 60 minutes

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~48 m, 60 m; 60 minutes

This trial's timeline: 3 weeks for screening, Varies for treatment, and 48 m, 60 m; 60 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in ASD Symptom Severity

Change in Cognitive Functioning

Secondary outcome measures

ASD Symptoms - secondary measure1

ASD symptoms - secondary measure2

ASD symptoms - secondary measure3

+6 more

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Enhanced early detectionExperimental Treatment1 Intervention

Providers will receive training to administer enhanced early detection strategies.

Group II: Usual careActive Control1 Intervention

Providers will not change their early detection strategies, but will be monitored.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of California, DavisOTHER

911 Previous Clinical Trials

4,707,496 Total Patients Enrolled

University of ConnecticutOTHER

183 Previous Clinical Trials

156,086 Total Patients Enrolled

Drexel UniversityLead Sponsor

150 Previous Clinical Trials

45,678 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the main aim of this medical experiment?

"This medical trial's primary outcome entails assessing the alteration in ASD Symptom Severity over a sixty minute window. Additionally, secondary endpoints include Kindergarten Readiness as evaluated with Developmental Indicators for the Assessment of Learning-4, Adaptive Functioning via Vineland Adaptive Behavior Scales-3, and an additional measure of ASD Symptoms through BOSCC."

Answered by AI

Is eligibility for this medical experiment limited to those over 25 years of age?

"To qualify for this investigation, patients must be between 16 and 58 months of age. Subsequently, 212 trials are available to minors while 41 studies are geared towards the elderly population."

Answered by AI

Could I potentially qualify to partake in this medical trial?

"This clinical trial is enrolling 3,450 individuals diagnosed with autism spectrum disorder who are between 16 and 58 months of age. The primary requirement for admission to the study is that the child must have attended an 18 month visit at a participating pediatric practice."

Answered by AI

What potential risks come with utilizing Enhanced early detection?

"We have determined that Enhanced Early Detection has a safety rating of 3, due to it being in Phase 4 and having been approved by the relevant authorities."

Answered by AI

Are there any opportunities to participate in this research endeavor at present?

"Per information hosted on clinicaltrials.gov, this medical research is not actively seeking patients at the present moment. The trial was initially posted in November 2017 and last updated September 2021; however, 252 other trials are presently accepting candidates for participation."

Answered by AI

Recent research and studies

TrialsJournal

Connecting the Dots: A Cluster-randomized Clinical Trial Integrating Standardized Autism Spectrum Disorders Screening, High-quality Treatment, and Long-term Outcomes

McClure, Leslie A., Nora L. Lee, Katherine Sand, Giacomo Vivanti, Deborah Fein, Aubyn Stahmer, and Diana L. Robins. 2021. “Connecting the Dots: A Cluster-randomized Clinical Trial Integrating Standardized Autism Spectrum Disorders Screening, High-quality Treatment, and Long-term Outcomes”. Trials. Springer Science and Business Media LLC. doi:10.1186/s13063-021-05286-6.

clinicaltrials.govStudy

Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes

Diana Robins 2017. "Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03333629.